玻璃体腔注射齐夫-阿柏西普治疗无应答的新生血管性年龄相关性黄斑变性的1年结局
这项回顾性研究纳入16只眼(14例患者)对贝伐珠单抗和雷珠单抗无应答的新生血管性年龄相关性黄斑变性眼,接受按需玻璃体腔注射齐夫-阿柏西普(1.25 mg/0.05 mL)治疗12个月;结果显示平均最佳矫正视力无变化,治疗间隔延长,解剖学指标无显著差异,无不良事件。
要点
- 对贝伐珠单抗和雷珠单抗无应答的nAMD眼接受IVZ治疗12个月,平均logMAR BCVA无变化(p=0.978)。
- IVZ治疗期间平均治疗间隔为114.4±67.1天,长于治疗前76.3±54.6天(p=0.03)。
- 12个月时平均CMT、RPED高度及IRF和SRF存在情况与基线无显著差异,未观察到不良事件。
核心结论
- IVZ延长了无应答者的治疗间隔,但视觉和解剖学结局无显著变化。
研究设计与样本
- 回顾性研究,纳入16只眼(14例患者)对贝伐珠单抗和雷珠单抗无应答的nAMD眼,接受按需IVZ(1.25 mg/0.05 mL)治疗12个月。
主要发现
- 基线及IVZ治疗后的平均logMAR BCVA无变化(p=0.978)。
- 12个月内平均IVZ注射次数为5.9±3.3次,换用IVZ前平均抗VEGF注射次数为8.4±4.7次。
- IVZ治疗期间平均治疗间隔为114.4±67.1天,长于IVZ治疗前的76.3±54.6天(p=0.03)。
- 5只眼(31.25%)视力提高至少0.1 logMAR,3只眼(18.75%)BCVA稳定(在0.1 logMAR以内),8只眼(50%)BCVA下降至少0.1 logMAR。
- 12个月时平均CMT、RPED高度及IRF和SRF存在情况与基线相比无显著差异,未观察到不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate 12-month outcome of intravitreal ziv-aflibercept (IVZ) therapy in eyes with neovascular age-related macular degeneration (nAMD) that are non-responsive to bevacizumab and ranibizumab. METHODS: This retrospective study included 16 eyes (14 patients) with nAMD who were on prior treatment with bevacizumab and ranibizumab and were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months. The primary outcome measure was the mean change in best corrected visual acuity (BCVA) and secondary outcome measures included mean change in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, longest treatment free interval, presence of subretinal fluid (SRF) and intraretinal fluid (IRF) and adverse events. RESULTS: There was no change in the mean logarithm of minimum angle of resolution (logMAR) BCVA at baseline and following treatment with IVZ therapy (p=0.978). The mean number of IVZ injections during 12 months was 5.9±3.3, and the mean number of antivascular endothelial growth factors (VEGFs) injections prior to switching to IVZ was 8.4±4.7. The mean treatment free interval was longer during IVZ therapy (114.4±67.1 days) compared with 76.3±54.6 days before IVZ therapy (p=0.03). Five (31.25%) eyes had visual gains of at least 0.1 logMAR, 3 (18.75%) eyes had stable BCVA (within 0.1 logMAR) and 8 (50%) eyes had BCVA decline of at least 0.1 logMAR. There was no significant difference in the mean CMT, RPED heights and presence of IRF and SRF at 12 months compared with baseline. No adverse events were noted. CONCLUSION: IVZ increased the treatment free interval in non-responders but no significant change in visual and anatomic outcomes.
引用
- Braimah IZ, Agarwal K, Mansour A, et al. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration. Br J Ophthalmol. 2017. PMID: 28596286. doi:10.1136/bjophthalmol-2017-310318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。